Header

Prof. Dr. T. Todenhöfer

Prof. Dr. Tilman Todenhöfer ist Facharzt für Urologie, Zusatzbezeichnung Medikamentöse Tumortherapie, leitender Prüfarzt.

Prof. Dr. Tilman Todenhöfer

School and Graduation

1992 - 2001 Secondary school Geschwister-Scholl Gymnasium Tübingen

2002 - 2004
School of Medicine University of Rostock 
2004 - 2009 School of Medicine University of Freiburg

Medical Education

01.Dec.2009 Approbation
07.Jul.2016 Certified Urologist
22.Nov.2016 Appointment as Associate Professor (Habilitation), University of Tuebingen
11. Feb. 2019 Appointment as Professor (apl. Professur) University of Tuebingen
03. Jun. 2017 Certification as Fellow of the European Board of Urology

Clinical Appointments

01/2010 – 07/2016 Residency, Dept. of Urology, University Hospital Tübingen (Chairman Prof. A. Stenzl)
07/2016 – 01/2017 Senior Physician, Dept. of Urology, University Hospital Tübingen
02/2017-03/2019 Faculty Member,Dept. of Urology, University Hospital Tübingen
10/2017-03/2019 Head Clinical Trial Unit Dept. of Urology, University Hospital Tübingen
05/2019 shareholder, member of the team Studienpraxis Urologie Nürtingen

Postdoctoral Fellowship

05/2014-10/2015 Postdoctoral Research Fellow, University of British Columbia (Supervisors: Dr. Peter Black, Dr. Kim Chi) 

Role in Clinical Trials

Since 05/2012 Subinvestigator Clinic for Urology Tübingen
Since 06/2012 Subinvestigator Studienpraxis Urologie Nürtingen
10/2017-05/2019 head of the study center Clinic for Urology Tübingen

GCP Training

2/2012 Good Clinical Practice (GCP) 8-hours training
9/2014, 7/2017 CenTrial GmbH Tübingen

Role as reviewer for

  BMC Urology, BMC Cancer, Biologics: Targets and Therapy, Carcinogenesis, Cancer Treatment Reviews, Clinical Interventions in Aging, Experimental and Clinical Endocrinology and Diabetes, European Urology, European Urology Focus, International Journal of Urology, Journal of Cancer Research and Clinical Oncology, Journal of Experimental and Clinical Cancer Research, Journal of Urology, Lancet Oncology, Molecular Cancer Research, Molecular Diagnosis & Therapy, Nature Reviews Urology, Oncotarget, PLOSone, Scientific Reports, Urologic Oncology, Radiotherapy & Oncology

Editor

 

Disease Markers

Translational Andrology and Urology

Awards

2018 Best Poster Award Annual Meeting European Association of Urology (EAU) (Prostate Cancer)
2016 Maximilian Nitze Award German Society of Urology
2016 Best Poster Award Annual Meeting American Urologic Association (AUA) (Bladder Cancer)
2016 Best Poster Award Annual Meeting European Association of Urology (EAU) (CRPC)
2015 C.E. Alken Alken Award
2015 Research Award Canadian Urologic Association (CUA)
2015 Prostate Cancer Research Award German Society for Urology (DGU)
2014 Research Award Canadian Uroonocology Group (CUOG)
2014-2015 Scholarship German Cancer Foundation
2015 Best Poster Annual Meeting American Urologic Association (AUA) (Prostate Cancer)
2014 John Blandy Award British Association of Urological Surgeons
2013 Best Poster Annual Award Congress European Assocation of Urology (EAU) (Bladder Cancer)
2012 Best Poster Annual Meeting German Society for Urology (Prostate Cancer)
2012 Best Poster Annual Meeting German Society for Urology (Bladder Cancer)
2005-2009 Scholar German National Academic Foundation (Studienstiftung)

Memberships in Societies

Since 2016 Member Working Group Urologic Research (AuF) German Society for Urology
Since 2015 Expert Consultant Subcomittee for metastatic Prostate Cancer Multimedia Learning Committee Societe International de Urologie (SIU)

Prof. Dr. Tilman Todenhöfer

Prof. Dr. Tilman Todenhöfer: 
+49 (0) 1520 ..1622246

Wir beantworten jede Kontaktaufnahme persönlich!

Prof. Dr. Tilman Todenhöfer

Chance durch klinische Studien

Aus dem Angebot renommierter Sponsoren wählen wir sorgfältig und im individuellen Interesse des Patienten Studien mit neuen oder vergleichenden Therapieoptionen.

 

Wir unterstützen alle Beteiligten (Patient, Facharzt, Hausarzt) bei der Durchführung der klinischen Studien.

 

 

Studien